Current Treatment Options in Oncology最新文献

Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer. 激素受体阳性早期乳腺癌系统治疗的最新进展。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-10-03 DOI: 10.1007/s11864-024-01258-5

Emily Hsu, Sabrina M Arezo, Stephanie L Graff

{"title":"Updates in Systemic Treatment of Hormone Receptor-Positive Early-Stage Breast Cancer.","authors":"Emily Hsu, Sabrina M Arezo, Stephanie L Graff","doi":"10.1007/s11864-024-01258-5","DOIUrl":"https://doi.org/10.1007/s11864-024-01258-5","url":null,"abstract":"Opinion statement: Hormone-receptor positive (HR +) and human epidermal growth factor receptor 2 (HER2) negative early breast cancer (eBC) is a heterogeneous disease with several contributing factors for increased risk of recurrence, including tumor features, individual biomarkers, and genomic risk. The current standard approach in the management of HR + /HER2neg eBC includes chemotherapy and endocrine therapy (ET), and additional therapies based on risk profile, menopausal status, and genetics are sometimes appropriate. The risk of recurrence is more pronounced in patients with high-risk eBC including large tumor size, nodal involvement, high proliferative index, and genetic predisposition. In premenopausal patients with high-risk eBC, ovarian function suppression in combination with adjuvant ET improves survival. In postmenopausal patients, extended aromatase inhibitor (AI) therapy can be considered. Recent trials have identified novel treatment approaches to reduce the risk of recurrence in high-risk HR + /HER2neg eBC including the addition of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors to adjuvant ET. For patients with germline BRCA1/BRCA2 mutations, adjuvant poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors have been shown to improve overall survival (OS). However, despite these recent advances, the risk of recurrence remains substantial, highlighting an area of unmet need. There are several ongoing clinical trials further investigating the role of CDK 4/6 inhibitors and immunotherapy in high-risk HR + /HER2neg eBC.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of SIRT1 in Leukemia. SIRT1 在白血病中的作用

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-10-02 DOI: 10.1007/s11864-024-01265-6

Zhongqi Wu, Tianxin Lyu, Leizhen Wu, Hui Yang, Wenqiang Li

引用次数: 0

Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer. FTD/TPI + 贝伐珠单抗联合疗法在不可切除转移性结直肠癌治疗中的临床试验数据回顾。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-26 DOI: 10.1007/s11864-024-01261-w

Thierry André, Eric Van Cutsem, Julien Taieb, Marwan Fakih, Gerald W Prager, Fortunato Ciardiello, Alfredo Falcone, Mark Saunders, Nadia Amellal, Lucas Roby, Josep Tabernero, Per Pfeiffer

{"title":"Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer.","authors":"Thierry André, Eric Van Cutsem, Julien Taieb, Marwan Fakih, Gerald W Prager, Fortunato Ciardiello, Alfredo Falcone, Mark Saunders, Nadia Amellal, Lucas Roby, Josep Tabernero, Per Pfeiffer","doi":"10.1007/s11864-024-01261-w","DOIUrl":"https://doi.org/10.1007/s11864-024-01261-w","url":null,"abstract":"Opinion statement: Recommended first and second line treatments for unresectable metastatic colorectal cancer (mCRC) include fluorouracil-based chemotherapy, anti-vascular endothelial growth factor (VEGF)-based therapy, and anti-epidermal growth factor receptor-targeted therapies. In third line, the SUNLIGHT trial showed that trifluridine/tipiracil + bevacizumab (FTD/TPI + BEV) provided significant survival benefits and as such is now a recommended third line regimen in patients with refractory mCRC, irrespective of RAS mutational status and previous anti-VEGF treatment. Some patients are not candidates for intensive combination chemotherapy as first-line therapy due to age, low tumor burden, performance status and/or comorbidities. Capecitabine (CAP) + BEV is recommended in these patients. In the SOLSTICE trial, FTD/TPI + BEV as a first line regimen in patients not eligible for intensive therapy was not superior to CAP + BEV in terms of progression-free survival (PFS). However, in SOLSTICE, FTD/TPI + BEV resulted in similar PFS, overall survival, and maintenance of quality of life as CAP + BEV, with a different safety profile. FTD/TPI + BEV offers a possible first line alternative in patients for whom CAP + BEV is an unsuitable treatment. This narrative review explores and summarizes the clinical trial data on FTD/TPI + BEV.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Treatment of Anemia in Lower-Risk Myelodysplastic Syndrome. 更正：低风险骨髓增生异常综合症患者的贫血治疗。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-23 DOI: 10.1007/s11864-024-01263-8

Muriel R Battaglia, Joseph Cannova, Rafael Madero-Marroquin, Anand A Patel

引用次数: 0

Diagnosis and Treatment of Myxoid Liposarcoma. 肌样脂肪肉瘤的诊断和治疗。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-20 DOI: 10.1007/s11864-024-01262-9

Guoxin Qu, Chunlei Zhang, Zhichao Tian, Weitao Yao

{"title":"Diagnosis and Treatment of Myxoid Liposarcoma.","authors":"Guoxin Qu, Chunlei Zhang, Zhichao Tian, Weitao Yao","doi":"10.1007/s11864-024-01262-9","DOIUrl":"https://doi.org/10.1007/s11864-024-01262-9","url":null,"abstract":"Opinion statement: Myxoid liposarcoma (MLS) is a rare subtype of soft tissue sarcoma that distinguishes itself from conventional subtypes through its propensity for extrapulmonary metastasis. The distinctive magnetic resonance imaging (MRI) characteristics of MLS render it an invaluable tool for identifying primary and secondary lesions. Pathologically, MLS is characterized by the FUS-DDIT3 gene fusion. Accurate diagnosis, facilitated by MRI and pathological assessment, is critical for prognostication and the formulation of appropriate treatment strategies. Surgery remains the cornerstone of local management for MLS. The combination of surgery and radiotherapy can significantly reduce the local recurrence rate in MLS, as it is highly sensitive to both radiotherapy and chemotherapy. Additionally, for high-risk MLS cases with a large tumor diameter, chemotherapy has been shown to improve survival. The comprehensive treatment approach for MLS demonstrates superior local recurrence rates and survival rates compared to most soft tissue sarcomas. Current research focuses on developing effective therapies for unresectable or advanced disease based on genomic and phenotypic characteristics as well as the immune-tumor microenvironment.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of Pulmonary Toxicities Associated with Systemic Therapy in Non Small Cell Lung Cancer. 非小细胞肺癌全身治疗相关肺部毒性的处理。

IF 3.8 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-20 DOI: 10.1007/s11864-024-01257-6

Marko Velimirovic, Matthew Brignola, Emily Chheng, Michael Smith, Khaled A Hassan

{"title":"Management of Pulmonary Toxicities Associated with Systemic Therapy in Non Small Cell Lung Cancer.","authors":"Marko Velimirovic, Matthew Brignola, Emily Chheng, Michael Smith, Khaled A Hassan","doi":"10.1007/s11864-024-01257-6","DOIUrl":"https://doi.org/10.1007/s11864-024-01257-6","url":null,"abstract":"Opinion statement: Drug-induced pneumonitis is a common adverse event that may occur during lung cancer systemic therapy. The incidence/prevalence of this side effect has increased due to recent extensive use of immunotherapy. Although pneumonitis prevalence is increased with the use of immune checkpoint inhibitors, it is also associated with chemotherapy and targeted therapy. Pneumonitis can occur early after drug exposure or present after several cycles of treatment. Its severity can range from insidious to fulminant, leading to hospitalization. In most cases, the diagnosis is made based on medical history, temporal correlation with use of lung cancer systemic therapy, and computed tomography (CT) findings. In the majority of cases, stopping the offending drug and use of corticosteroids is the sufficient treatment; however, patients with more severe forms of pneumonitis require additional immunosuppressive agents. In this review, we address pneumonitis caused by chemotherapy, antibody-drug conjugates, targeted therapy, or immunotherapy, and provide a detailed management approach.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":3.8,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of Nursing in the Delivery of Cardio-Oncology 护理在心外科肿瘤治疗中的作用

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-17 DOI: 10.1007/s11864-024-01241-0

Anecita Fadol, Lisa Nodzon, Geraldine Lee

{"title":"The Role of Nursing in the Delivery of Cardio-Oncology","authors":"Anecita Fadol, Lisa Nodzon, Geraldine Lee","doi":"10.1007/s11864-024-01241-0","DOIUrl":"https://doi.org/10.1007/s11864-024-01241-0","url":null,"abstract":"Nurses are the “heart of patient care” and in the forefront of the health care delivery for cardio-oncology patients. Nurses play a critical central role in maximizing longitudinal health of cancer patients and survivors through the prevention of cardiovascular complications throughout the patient’s cancer care journey. Nurses function in a variety of roles such as nurse clinicians, advanced practice nurses (APNs)or nurse practitioners (NPs), patient educators, managers, nurse navigators or nurse researchers. The role of nurses, particularly the advanced practice nurses as key members in delivering cardio-oncology care is evolving. However, despite the rapidly increasing growth of cardio oncology programs globally, a pivotal need remains to develop and provide formalized training programs for nurses, NPs and APNs. At present, no formal academic cardio-oncology nurse training program or certification exists. There is clearly more work to be done on the role of nurses in cardio-oncology care. As cardio-oncology evolves to become a key specialty with dedicated services being established across the globe, the role of the nurse in delivering this service is critical and a concerted collaborative approach between the two distinct specialties of cardiology and oncology needs to ensure the nursing workforce is educationally prepared and confident to treat and manage cardio-oncology patients.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142252536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research Progress on Ferroptosis in Multiple Myeloma 多发性骨髓瘤中的铁蛋白沉积研究进展

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-17 DOI: 10.1007/s11864-024-01250-z

Po Li, Tianxin Lyu

引用次数: 0

Myeloproliferative Neoplasms and Cardiovascular Disease: A Review 骨髓增生性肿瘤与心血管疾病：综述

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-16 DOI: 10.1007/s11864-024-01255-8

Orly Leiva, Olivia Liu, Sophia Zhou, Joan How, Michelle Lee, Gabriela Hobbs

引用次数: 0

The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy 晚期肝细胞癌的治疗趋势：免疫疗法与靶向疗法相结合

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2024-09-11 DOI: 10.1007/s11864-024-01246-9

Heng Dong, Zhengguo Zhang, Mengjie Ni, Xiaoyun Xu, Yifeng Luo, Yaru Wang, Haiyun Zhang, Jianxiang Chen

引用次数: 0